Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2018

Primary Completion Date

October 18, 2018

Study Completion Date

March 28, 2019

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL

BCD-132

Dose Escalation Study

Trial Locations (5)

Pavlov First Saint Petersburg State Medical University, Saint Petersburg

City Hospital #15, Moscow

Moscow Regional Research and Clinical Institute, Moscow

Scientific Center of Neurology, Moscow

Institute of the Human Brain n. a. N.P. Bekhtereva Russian Academy of Sciences, Saint Petersburg